Status | Study |
Enrolling by invitation |
Study Name: Gene-activated Bone Substitute for Maxillofacial Bone Regeneration Condition: Bone Cysts Bone Atrophy Bone Date: 2017-03-05 Interventions: Device: Gene-activated matrix (OCP + plasmid DNA with VEGF gene) Bone grafting procedure with investigat |
Recruiting |
Study Name: Use of Stem Cells Cultured on a Scaffold for the Treatment of Aneurysmal Bone Cysts (ABC) Condition: Aneurysmal Bone Cyst Date: 2017-02-23 Interventions: Biological: MSC-PLGA Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL. |
Recruiting |
Study Name: Familial Investigations of Childhood Cancer Predisposition Condition: Acute Leukemia Adenomatous Polyposis Adrenocortical Carcin Date: 2017-02-08 |
Completed |
Study Name: Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas (BCC) in Gorlin Syndrome Patients Condition: Basal Cell Nevus Syndrome Date: 2016-04-27 Interventions: Drug: patidegib patidegib gel |
Recruiting |
Study Name: Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas Condition: Basal Cell Carcinoma Date: 2015-12-14 Interventions: Drug: Vismodegib Vismodegib 150 mgs po qd for 3 months |
Recruiting |
Study Name: Quantitative Ultrasound for the Evaluation of Simple Bone Cyst Healing Condition: Simple Bone Cyst Date: 2015-11-25 Interventions: Device: Sunlight Omnisense Quantitative Ultrasound Ultrasound |
Recruiting |
Study Name: Calcium Phosphate Cement Registry (CPC Registry) Condition: Bone Disease Fracture Bone Bone Cyst Date: 2015-10-12 |
Completed |
Study Name: Complete Twelve Month Bone Remodeling With a Bi-phasic Injectable Bone Substitute in Benign Bone Tumors Condition: Bone Cyst Date: 2015-09-30 Interventions: Device: CERAMENT™ |BONE VOID FILLER Implantation of bi-phasic ceramic bone substitute to provide b |
Recruiting |
Study Name: A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma Condition: Basal Cell Nevus Syndrome Skin Neoplasm Nodular Basal Cell Date: 2015-09-10 Interventions: Biological: ASN-002 ASN‐ |
Recruiting |
Study Name: Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) Condition: Basal Cell Carcinoma in Basal Cell Nevus Syndrome Date: 2015-01-21 Interventions: Drug: SUBA-Itraconazole Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily. |